Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared an article on X, on Trastuzumab rezetecan and pyrotinib plus capecitabine:
Title: Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
Authors: Herui Yao, Qingyuan Zhang, Huiping Li, Yongmei Yin, Shusen Wang, Quchang Ouyang, Tao Sun, Wei Li, Xiaojia Wang, Min Yan, Biyun Wang, Jing Cheng, Zhongsheng Tong, Wei Wei, Xinshuai Wang, Weimin Xie, Zhengkui Sun, Peng Yuan, Cuizhi Geng, Lu Gan, Xinghua Han, Wenfeng Li, Shoubing Zhou, Xi Yan, Jinnan Gao, Tienan Yi, Jingna Wu, Zhaofeng Niu, Fangmeng Fu, Jianyun Nie, Yongsheng Wang, Bing Zhao, Zhiyong Wu, Zhengqiu Zhu, Yaping Yang, Jianli Zhao, Zhen Sheng, Ying Zhang, Lin Cheng, Xiaoyu Zhu, Erwei Song
Quoting an older post:
“HORIZON-Breast01:
In previously treated HER2+ a/mBC, SHR-A1811 (T-Rezetecan) achieved a major PFS advantage versuss pyrotinib + cape (30.6 mo versus 8.3 mo; HR 0.22), with ORR 82% vs 56% and low ILD (2.8%).
The magnitude of benefit is impressive – though prior T-DM1 exposure was only ~4%, an important factor when interpreting the results.”
Other articles featuring Yakup Ergün on OncoDaily.
